• Corpus ID: 5875173

The Efficacy of CD 3 x CD 19 Bispecific Monoclonal Antibody ( BsAb ) in a Clonogenic Assay : The Effect of Repeated Addition of BsAb and Interleukin-2

@inproceedings{Geerars2000TheEO,
  title={The Efficacy of CD 3 x CD 19 Bispecific Monoclonal Antibody ( BsAb ) in a Clonogenic Assay : The Effect of Repeated Addition of BsAb and Interleukin-2},
  author={Anette J. G. Geerars and Ba De and Bert J.E.G. Bast and Bert and D R Gast},
  year={2000}
}
To evaluate the potency by which human T cells are targeted and activated by bispecific monoclonal antibodies (BsAbs) t o lyse tumor cells, a clonogenic assay was developed. The efficacy of a CD3xCD19 BsAb binding to both the CD3 T-cell antigen and the CD19 B-cell antigen was already proven in "Cr-release assays and in 3-day activation cultures. To achieve more quantitative results, a 14-day clonogenic assay, based on limiting-dilution, was performed for the determination of the initial and… 
5 Citations

Figures and Tables from this paper

The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct
TLDR
Dexamethasone did not detectably inhibit the cytotoxic activity of MT103-activated T cells against a human B lymphoma line as investigated with lymphocytes from 12 human donors, and qualify as a potential co-medication for therapeutic BiTE molecules and other cytot toxic T cell therapies for treatment of cancer.
Administration of BiMAb‐Retargeted T Cells in a Rat Hepatic Metastases Colon Tumour Model Results in T‐Cell Tumour Infiltration Independent of the Route of Administration
TLDR
There was no difference between the number of T’cells that reached the portal tracts, central veins of parenchyma of the liver, after loco‐regional or systemic administration, in contrast to the interleukin (IL)‐2 activated NK (A‐NK) cells biodistribution studies earlier performed in the same animal model in the authors' laboratory.
Treatment of patients with malignant lymphomas with monoclonal antibodies
TLDR
A humanized anti-CD20 antibody showed excellent results in chemotherapy refractory lymphomas and has recently been approved for clinical application in CD20 positive B cell lymphomas.
Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients
TLDR
The authors found that the key lies in the predominant isoform of a receptor that natural killer cells use to interact with neuroblastoma cells and that the balance between isoforms of this receptor on a patient’s cells can help predict survival.
Coomassie Blue-stained SDS / Polyacrylamide Gel of Purified bSCCD 19 xCD 3 plug
Jonge et al Cancer Immunol immunother 45:162-165, 1997.* Rudikoff et al PNAS 79:1979, 1982.* Mack et al PNAS 92:7021-25, 1995.* Bohlen et al Blood 82:1803-12, 1993.* Sompuram et al., The Journal of

References

SHOWING 1-10 OF 25 REFERENCES
Killing of autologous B-lineage malignancy using CD3 x CD19 bispecific monoclonal antibody in end stage leukemia and lymphoma.
TLDR
Various types of experiments showed that efficient CD3 x CD19 BsAb-mediated cytolytic capacity was not dependent on expression of either of these surface proteins, which contrasts with normal major histocompatibility complex-restricted antigen-specific cytotoxicity and may be essential for effective in vivo application of this Bs Ab.
Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype x anti-CD3).
TLDR
In vivo studies demonstrate that this bispecific mAb could efficiently target T cells towards the tumor cells, resulting in long term survival and cure of the lymphoma.
Bispecific IgG and IL-2 therapy of a syngeneic B-cell lymphoma in immunocompetent mice.
  • G. Weiner
  • Chemistry, Medicine
    International journal of cancer. Supplement = Journal international du cancer. Supplement
  • 1992
Bispecific antibody (bsAb) which binds to CD3 and a tumor-associated antigen can induce lysis of tumor cells by T cells. Lymphocytes targeted by bsAbs are also capable of inhibiting the growth of
Bispecific antibody therapy of two murine B-cell lymphomas.
TLDR
Immunotherapy of tumor bearing animals demonstrated that bsAbs could efficiently target T cells towards the tumor cells, that tumor cell--T cell bridging is established in vivo, and that both T cell subsets contribute to tumor regression resulting in long-term survival and cure of the lymphomas.
Functional studies with anti-CD3 heavy chain isotype switch-variant monoclonal antibodies. Accessory cell-independent induction of interleukin 2 responsiveness in T cells by epsilon-anti-CD3.
TLDR
It was demonstrated that the epsilon-anti-CD3 antibody, in comparison with the other variant mAb, has a relatively low avidity for the CD3 antigen, possibly as a result of monovalent binding.
T-cell killing of target cells induced by hybrid antibodies: comparison of two bispecific monoclonal antibodies.
TLDR
Mixed isotype hybrid antibodies may have some advantages for eliciting T-cell-mediated killing of tumor cell targets by exhibiting a better therapeutic ratio of target cell to effector cell cytotoxicity.
Characterization of IgG FcR-mediated proliferation of human T cells induced by mouse and human anti-CD3 monoclonal antibodies. Identification of a functional polymorphism to human IgG2 anti-CD3.
TLDR
It was found that leukocytes in a normal donor population display a functional polymorphism that is inversely related to the previously defined Fc gamma RII-polymorphism to mIgG1 anti-CD3 mAb, which could be confirmed in T cell activation studies using hFc Gamma RIIa-transfected mouse fibroblasts.
Effective purging of bone marrow by a combination of immunorosette depletion and complement lysis.
TLDR
The combination of the two methods results in a highly efficient purging procedure for the removal of cALL+ cells from autologous bone marrow cells.
The improved lytic function and in vivo efficacy of monovalent monoclonal CD3 antibodies
TLDR
In a preliminary clinical study in one patient with a T lymphoma in leukemic phase this monovalent CD3 antibody was found to be very effective in depleting CD3 tumor cells in the peripheral blood and bone marrow.
Comparative efficiencies of bispecific F(ab'gamma)2 and chimeric mouse/human IgG antibodies in recruiting cellular effectors for cytotoxicity via Fc gamma receptors.
TLDR
It is suggested that the chimeric, Fc-containing derivatives mediate tumour cell lysis principally through Fc gamma RIII on NK cells, in contrast to the situation with the chick red blood cells where the Chimeric derivatives appear capable of lysing erythrocytes by utilizing either monocytes or NK cells.
...
1
2
3
...